CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced today that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia.
-- PYK-2101 aims to provide rapid visual recovery, enhanced outcomes, and a dramatically improved post-operative experience for patients with retinal detachment, addressing critical unmet needs-- ...
-- Results to date demonstrate rapid post-surgical visual recovery with no serious adverse events and meet or exceed FDA target rates for safety and effectiveness – -- Data presented today at ...
(MENAFN- PR Newswire) Please contact the Company directly for more information regarding the Eyecelerator presentation. "PYK-2101 has the potential to offer enormous benefits to patients undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results